Go to content
UR Home

EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients

URN to cite this document:
DOI to cite this document:
Wöhl, D. S. ; James, B. ; Götz, M. ; Brennfleck, F. ; Holub-Hayles, I. ; Mutzbauer, I. ; Baccar, S. ; Brunner, S. M. ; Geissler, E. K. ; Schlitt, H. J. ; Vondran, Florian W. R. ; Herden, Uta ; Mittler, Jens ; Neumann, Ulf Peter ; Nadalin, Silvio ; Schnitzbauer, Andreas A. ; Rauchfuß, Falk ; Braun, Felix ; Willuweit, Katharina ; Pratschke, Johann ; Berg, Thomas ; Vogel, Thomas ; Merle, Uta ; Croner, Roland
[img]License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 23 May 2023 05:16


Background Graft rejection and chronic CNI toxicity remain obstacles to organ transplant success. Current formulations of tacrolimus, such as Prograf® and Advagraf™, exhibit limitations in terms of pharmacokinetics and tolerability, related in part to suboptimal bioavailability. As dosing non-compliance can result in graft rejection, the once daily formulation of tacrolimus, Advagraf™, was ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons